Areas of Focus
- Basic research on breast cancer
- Clinical translational research on molecular imaging and precise tumor treatment
- Research on intelligent medicine and multidisciplinary comprehensive diagnosis and treatment of tumors
Work Experience
- 2017~Present - Xiamen University Affiliated Xiang'an Hospital - Executive Dean, Director of Oncology Diagnosis and Treatment Center
- 2008~2017 - Shantou University Medical College Affiliated Cancer Hospital - Dean, Director of Breast Center
- 2005~2008 - Merck & Co. - Senior Scientist
- 1999~2004 - Harvard Medical School Dana-Farber Cancer Institute - Postdoctoral Researcher
- 1987~1993 - China Medical University First Affiliated Hospital - Resident Physician, Attending Physician, Lecturer
Academic Background & Achievements
- 1995.04~1999.03 Doctor of Surgery: Fukushima Medical University, Japan
- 1990.09~1995.12 Doctor of Medicine: China Medical University
- 1981.09~1987.07 Bachelor of Medicine: China Medical University, Japanese Medicine
Publications
- Bioluminescent imaging of CDK2 inhibition in vivo, Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Shapiro G, Zhelev N, Kaelin Jr WG, 2004
- Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways, Zhang GJ, Chen TB, Hargreaves R, Sur C, Williams Jr DL, 2008
- Biodegradable Nanoprobe for NIR-II Fluorescence Image-Guided Surgery and Enhanced Breast Cancer Radiotherapy Efficacy, Yang RQ, Wang PY, Lou KL, Dang YY, Tian HN, Li Y, Gao YY, Huang WH, Zhang YQ, Liu XL, Zhang GJ, 2022
- RGD-functionalised melanin nanoparticles for intraoperative photoacoustic imaging-guided breast cancer surgery, Liu JJ, Wang Z, Nie LM, Zhu YY, Li G, Lin LL, Chen M, Zhang GJ, 2022
- The G1 phase optical reporter serves as a sensor of CDK4/6 inhibition in vivo, Guo CP, Guo YX, Liu JJ, Gao YY, Wei M, Zhao RJ, Chen M, Zhang GJ, 2021
- Surgical Navigation for Malignancies Guided by Near-Infrared-II Fluorescence Imaging, Yang RQ, Lou KL, Wang PY, Gao YY, Zhang YQ, Chen M, Huang WH, Zhang GJ, 2021
- MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines, Liang YK, Lin HY, Dou XW, Chen M, Wei XL, Zhang YQ, Wu Y, Chen CF, Bai JW, Xiao YS, Qi YZ, Kruyt FAE, Zhang GJ, 2018
- Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers, Koller M, Qiu SQ, Linssen MD, Jansen L, Kelder W, de Vries J, Kruithof I, Zhang GJ, Robinson DJ, Nagengast WB et al., 2018
- Comparison between the indocyanine green fluorescence and blue dye methods for sentinel lymph node biopsy using novel fluorescence image-guided resection equipment in different types of hospitals, He KS, Chi CW, Kou DQ, Huang WH, Wu JD, Wang YB, He LF, Ye JZ, Mao YM, Zhang GJ, Wang JD, Tian J, 2016
- Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-XL, without alteration of p53 protein levels, Zhang GJ, Kimijima I, Fukushima T, Sato H, Kanno M, Tsuchiya A, Abe R, 1999
Awards
- 2011: Distinguished Professor of the Changjiang Scholars Program
- 2016: National Special Support Program for High-Level Talents
- 2013: Government Special Allowance Certificate by the State Council
- 2009: National Candidate of the New Century Talents Project
- 2021: Fujian Province High-Level Talent Introduction A Category
- 2020: Fujian Province High-Level Innovative Talent Introduction
- 2018: Fujian Province Leading Talent in Universities
- 2016: Guangdong Special Support Program for Outstanding Talents
- 2020: Second Prize of the Chinese Anti-Cancer Association Science and Technology Award
- 2019: Second Prize of the Liaoning Province Science and Technology Progress Award
- 2017: Third Prize of the Guangdong Province Science and Technology Award
- 2020: Second Prize of the Xiamen City Science and Technology Progress Award
- 2019: Xiamen City High-Level Talent Introduction 'Double Hundred Plan'
- 2018: Xiamen City High-Level Health Leading Talent